Zdrowie i gospodarka · 15.07.1999
Draft Guidance for Industry: Clinical Development Programs for Drugs, Devices, and Biological Products Intended for the Treatment of Osteoarthritis (OA); Availability
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled ``Clinical Development Programs for Drugs, Devices, and Biological Products Intended for the Treatment of Osteoarthritis (OA).'' The draft guidance is intended to stimulate discussion about designing clinical programs for the development of drugs, devices, and biological products intended for the treatment of osteoarthritis (OA). This draft guidance reflects comments received in response to a previous draft version of the guidance available in February 1998.